Ensysce Biosciences, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

ENSC$0.36+10.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Federal grants	$493,104	$3,418,853	$3,184,314	$3,906,372
Operating expenses:
Research and development	2,954,909	1,690,674	6,763,866	3,416,807
General and administrative	1,279,290	1,083,433	3,879,569	3,643,223
Total operating expenses	4,234,199	2,774,107	10,643,435	7,060,030
Income (loss) from operations	(3,741,095)	644,746	(7,459,121)	(3,153,658)
Other income (expense):
Change in fair value of liability classified warrants	998	6,403	10,061	23,175
Interest expense, net	(6,369)	(4,063)	(13,385)	(1,279,691)
Other income and expense, net	17,338	14,683	54,227	(12,413)
Total other income (expense), net	11,967	17,023	50,903	(1,268,929)
Net income (loss)	$(3,729,128)	$661,769	$(7,408,218)	$(4,422,587)
Net loss attributable to noncontrolling interests	-	-	(166)	(74)
Deemed dividend related to warrants down round provision	-	-	-	290
Net income (loss) attributable to common stockholders	$(3,729,128)	$661,769	$(7,408,052)	$(4,422,803)
Net income (loss) per basic and diluted share:
Net income (loss) per share attributable to common stockholders, basic and diluted	$(1.29)	$1.00	$(3.42)	$(8.52)
Weighted average common shares outstanding, basic and diluted	2,886,059	659,361	2,168,247	518,838

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.